Collectively, the accumulated evidence on targeting PI3K pathway kinases and their associated pathways in gynecological cancers justify the continuing development of these inhibitors as a potential clinical combination therapy strategy. The gene discussed is PIK3CB; the disease is female reproductive organ cancer.